Atara Biotherapeutics, Inc. (LON:0HIY)
13.23
-0.97 (-6.84%)
At close: Nov 4, 2025
Atara Biotherapeutics Revenue
Atara Biotherapeutics had revenue of $17.58M USD in the quarter ending June 30, 2025, a decrease of -38.63%. This brings the company's revenue in the last twelve months to $188.67M, up 202.41% year-over-year. In the year 2024, Atara Biotherapeutics had annual revenue of $128.94M with 1,404.02% growth.
Revenue (ttm)
$188.67M
Revenue Growth
+202.41%
P/S Ratio
0.46
Revenue / Employee
$1.23M
Employees
153
Market Cap
63.00M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 128.94M | 120.37M | 1,404.02% |
| Dec 31, 2023 | 8.57M | -55.00M | -86.51% |
| Dec 31, 2022 | 63.57M | 43.23M | 212.55% |
| Dec 31, 2021 | 20.34M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| ConvaTec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |
Atara Biotherapeutics News
- 5 weeks ago - 4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals - Benzinga
- 5 weeks ago - 4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals - Benzinga
- 6 weeks ago - Atara Biotherapeutics (ATRA) Soars 10.0%: Is Further Upside Left in the Stock? - Nasdaq
- 2 months ago - Atara Biotherapeutics Announces Changes to Its Board of Directors - Business Wire
- 3 months ago - Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress - Business Wire
- 3 months ago - Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) - PRNewsWire
- 3 months ago - Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease - Business Wire
- 4 months ago - Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc. - PRNewsWire